Blood News and Research

RSS

Escalating inequality in cardiovascular health status between rich and poor

A new paper released by The George Institute for International Health is warning a cardiovascular disease based epidemic is gaining pace among many low- and middle-income countries (LMIC), exemplified at its worst in the world's largest populated countries – China and India.

3 Dec 2008

Lab on a microfluidic chip for the GP's surgery

If doctors were able to conduct efficient genetic analysis at the point of care, using inexpensive, portable equipment, it would revolutionise disease detection and treatment. European researchers are close to enabling this revolution.

2 Dec 2008

More evidence on why the Mediterranean diet is good for heart

Researchers have discovered one potential mechanism by which briefly cutting off, then restoring, blood flow to arteries prior to a heart attack lessens the damage caused, according to a study published today in the journal Cardiovascular Research.

2 Dec 2008

Study looks at mitral valve prolapse

Disturbing evidence of higher mortality and lower surgery rates in women versus men with mitral valve prolapse and severe leakage may be related to the complexity of evaluating the condition's severity in women, according to findings of a Mayo Clinic study published this month in the Annals of Internal Medicine.

1 Dec 2008

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

ViroPharma Inc. has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE).

1 Dec 2008

New method improves immunotherapy

A study published by Elsevier this month in Clinical Immunology, the official journal of the Clinical Immunology Society (CIS), describes a new method that facilitates the induction of a specific type of immune suppressive cells, called 'regulatory T cells' for therapeutic use.

1 Dec 2008

Scientists discover how ovarian tumors evade immune system

Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked.

1 Dec 2008

Poor quality HDL cholesterol bad for you

If you think your levels of "good cholesterol" are good enough, a new study published in the December 2008 issue of The FASEB Journal suggests that you may want to think again.

1 Dec 2008

Reprogrammable cell type depends on a single gene to keep its identity

Scientists at St. Jude Children's Research Hospital have discovered that a certain differentiated cell type is so ready to change its identity that it requires the constant expression of a gene called Prox1 to dissuade it.

1 Dec 2008

Prostate cancer tumors promote nerve growth

Prostate cancer - and perhaps other cancers - promotes the growth of new nerves and the branching axons that carry their messages, a finding associated with more aggressive tumors, said researchers from Baylor College of Medicine in the first report of the phenomenon that appears today in the journal Clinical Cancer Research.

1 Dec 2008

Vitamin D deficiency could lead to heart problems

Vitamin D deficiency - which is traditionally associated with bone and muscle weakness - may also increase the risk of cardiovascular disease (CVD).

1 Dec 2008

Genaera starts trial of Trodusquemine in overweight and obese type 2 diabetes

Genaera Corporation has announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics.

1 Dec 2008

New cream for vaginal dryness approved

Barr Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for Synthetic Conjugated Estrogens-A (SCE-A) 0.625 mg/g Vaginal Cream.

1 Dec 2008

FDA accepts Zevalin supplemental biologics license application

Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.

1 Dec 2008